Skip to content
healthcare.dev

RETEVMO

NDC 0002-6082, selpercatinib, tablet, coated, from Eli Lilly and Company.

Product NDC
0002-6082
Status
Listed
Labeler
Eli Lilly and Company
Dosage form
TABLET, COATED
Route
ORAL
Product type
HUMAN PRESCRIPTION DRUG
Marketing category
NDA
Application
NDA218160
DEA schedule
None
Request
curl https://api.healthcare.dev/v1/drugs/ndc/0002-6082 \
  -H "Authorization: Bearer $HDEV_API_KEY"

Product

Active ingredients and packages

Active ingredients

  • SELPERCATINIB80 mg/1

Pharmacologic classes

Breast Cancer Resistance Protein Inhibitors [MoA]; Cytochrome P450 2C8 Inhibitors [MoA]; Cytochrome P450 3A Inhibitors [MoA]; Kinase Inhibitor [EPC]; Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]; P-Glycoprotein Inhibitors [MoA]; Rearranged during Transfection (RET) Inhibitors [MoA]

Package NDCNDC-11Package
0002-6082-600000260826060 TABLET, COATED in 1 BOTTLE (0002-6082-60)

Linked data

RxNorm, label and prices

RxNorm concepts

Related lookups

  • FDA label sections

    GET /v1/drugs/labels/7fa848ba-a59c-4144-9f52-64d090f4d828

Use it

Look up 0002-6082 from code or an agent

curl
curl https://api.healthcare.dev/v1/drugs/ndc/0002-6082 \
  -H "Authorization: Bearer $HDEV_API_KEY"
MCP prompt
Using the healthcare.dev MCP server, look up NDC 0002-6082. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.

Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.